190 related articles for article (PubMed ID: 20671216)
21. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease.
Thieme K; Majumder S; Brijmohan AS; Batchu SN; Bowskill BB; Alghamdi TA; Advani SL; Kabir MG; Liu Y; Advani A
Sci Rep; 2017 Jun; 7(1):3442. PubMed ID: 28611444
[TBL] [Abstract][Full Text] [Related]
22. Activation of Galpha q-coupled signaling pathways in glomerular podocytes promotes renal injury.
Wang L; Fields TA; Pazmino K; Dai Q; Burchette JL; Howell DN; Coffman TM; Spurney RF
J Am Soc Nephrol; 2005 Dec; 16(12):3611-22. PubMed ID: 16267159
[TBL] [Abstract][Full Text] [Related]
23. Vascular Smooth Muscle-Specific EP4 Receptor Deletion in Mice Exacerbates Angiotensin II-Induced Renal Injury.
Thibodeau JF; Holterman CE; He Y; Carter A; Cron GO; Boisvert NC; Abd-Elrahman KS; Hsu KJ; Ferguson SS; Kennedy CR
Antioxid Redox Signal; 2016 Oct; 25(12):642-656. PubMed ID: 27245461
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C.
Fiebich BL; Schleicher S; Spleiss O; Czygan M; Hüll M
J Neurochem; 2001 Dec; 79(5):950-8. PubMed ID: 11739606
[TBL] [Abstract][Full Text] [Related]
25. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
[TBL] [Abstract][Full Text] [Related]
26. Podocyte-specific knockout of cyclooxygenase 2 exacerbates diabetic kidney disease.
Wang L; Sha Y; Bai J; Eisner W; Sparks MA; Buckley AF; Spurney RF
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F430-F439. PubMed ID: 28490532
[TBL] [Abstract][Full Text] [Related]
27. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
Majumder M; Landman E; Liu L; Hess D; Lala PK
Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
[TBL] [Abstract][Full Text] [Related]
28. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages.
Pavlovic S; Du B; Sakamoto K; Khan KM; Natarajan C; Breyer RM; Dannenberg AJ; Falcone DJ
J Biol Chem; 2006 Feb; 281(6):3321-8. PubMed ID: 16338931
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial Dysfunction in Podocytes Caused by CRIF1 Deficiency Leads to Progressive Albuminuria and Glomerular Sclerosis in Mice.
Na KR; Jeong JY; Shin JA; Chang YK; Suh KS; Lee KW; Choi DE
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063207
[TBL] [Abstract][Full Text] [Related]
30. The role of the podocyte in albumin filtration.
Brinkkoetter PT; Ising C; Benzing T
Nat Rev Nephrol; 2013 Jun; 9(6):328-36. PubMed ID: 23609563
[TBL] [Abstract][Full Text] [Related]
31. Activation of EP4 receptors contributes to prostaglandin E2-mediated stimulation of renal sensory nerves.
Kopp UC; Cicha MZ; Nakamura K; Nüsing RM; Smith LA; Hökfelt T
Am J Physiol Renal Physiol; 2004 Dec; 287(6):F1269-82. PubMed ID: 15292051
[TBL] [Abstract][Full Text] [Related]
32. EP4 knockdown alleviates glomerulosclerosis through Smad and MAPK pathways in mesangial cells.
Cao Y; Pan T; Chen X; Wu J; Guo N; Wang B
Mol Med Rep; 2018 Dec; 18(6):5141-5150. PubMed ID: 30320390
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Endocytosis of Clathrin-Mediated Angiotensin II Receptor Type 1 in Podocytes Augments Glomerular Injury.
Inoue K; Tian X; Velazquez H; Soda K; Wang Z; Pedigo CE; Wang Y; Cross E; Groener M; Shin JW; Li W; Hassan H; Yamamoto K; Mundel P; Ishibe S
J Am Soc Nephrol; 2019 Dec; 30(12):2307-2320. PubMed ID: 31511362
[TBL] [Abstract][Full Text] [Related]
34. Cosmc-dependent mucin-type
Stotter BR; Talbot BE; Capen DE; Artelt N; Zeng J; Matsumoto Y; Endlich N; Cummings RD; Schlondorff JS
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F518-F530. PubMed ID: 31904283
[TBL] [Abstract][Full Text] [Related]
35. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation.
Mendez M; LaPointe MC
Am J Physiol Heart Circ Physiol; 2005 May; 288(5):H2111-7. PubMed ID: 15626689
[TBL] [Abstract][Full Text] [Related]
36. Prostaglandin E2 receptors EP2 and EP4 are down-regulated in human mononuclear cells after injury.
Strong VE; Winter J; Yan Z; Smyth GP; Mestre JR; Maddali S; Schaefer PA; Yurt RW; Stapleton PP; Daly JM
Surgery; 2001 Aug; 130(2):249-55. PubMed ID: 11490357
[TBL] [Abstract][Full Text] [Related]
37. Adiponectin promotes functional recovery after podocyte ablation.
Rutkowski JM; Wang ZV; Park AS; Zhang J; Zhang D; Hu MC; Moe OW; Susztak K; Scherer PE
J Am Soc Nephrol; 2013 Feb; 24(2):268-82. PubMed ID: 23334396
[TBL] [Abstract][Full Text] [Related]
38. Characterization of prostanoid receptors in podocytes.
Bek M; Nüsing R; Kowark P; Henger A; Mundel P; Pavenstädt H
J Am Soc Nephrol; 1999 Oct; 10(10):2084-93. PubMed ID: 10505684
[TBL] [Abstract][Full Text] [Related]
39. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.
Li X; Pilbeam CC; Pan L; Breyer RM; Raisz LG
Bone; 2002 Apr; 30(4):567-73. PubMed ID: 11934647
[TBL] [Abstract][Full Text] [Related]
40. Extracellular matrix fibronectin increases prostaglandin E2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2.
Han S; Ritzenthaler JD; Wingerd B; Rivera HN; Roman J
J Biol Chem; 2007 Mar; 282(11):7961-72. PubMed ID: 17237224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
